Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1984 1
1986 1
1987 1
1989 1
1990 2
1991 1
1992 2
1993 1
1994 3
1995 2
1996 1
1997 3
1998 6
1999 9
2000 10
2001 10
2002 17
2003 20
2004 12
2005 15
2006 28
2007 29
2008 17
2009 26
2010 21
2011 22
2012 26
2013 34
2014 31
2015 34
2016 26
2017 22
2018 19
2019 28
2020 37
2021 44
2022 32
2023 44
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Results by year

Filters applied: . Clear all
Page 1
Gastrointestinal Stromal Tumors.
von Mehren M, Joensuu H. von Mehren M, et al. J Clin Oncol. 2018 Jan 10;36(2):136-143. doi: 10.1200/JCO.2017.74.9705. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220298 Free PMC article. Review.
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived g …
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progres …
Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Miettinen M, Lasota J. Miettinen M, et al. Semin Diagn Pathol. 2006 May;23(2):70-83. doi: 10.1053/j.semdp.2006.09.001. Semin Diagn Pathol. 2006. PMID: 17193820 Review.
Gastrointestinal (GI) stromal tumors (GISTs) are the most common mesenchymal tumors specific to the GI tract, generally defined as KIT (CD117)-positive tumors with a characteristic set of histologic features. ...Intestinal GISTs are a histologically more homo …
Gastrointestinal (GI) stromal tumors (GISTs) are the most common mesenchymal tumors specific to the GI tract, generally define …
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Maurer M, et al. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1067-1078. doi: 10.1016/j.jaip.2020.11.043. J Allergy Clin Immunol Pract. 2021. PMID: 33685605 Review.
Finally, we discuss targets for novel biologics and where we stand with their clinical development. These include IgE/ligelizumab, IgE/GI-310, thymic stromal lymphopoietin/tezepelumab, C5a receptor/avdoralimab, sialic acid-binding Ig-like lectin 8/lirentelimab, CD200R/LY34 …
Finally, we discuss targets for novel biologics and where we stand with their clinical development. These include IgE/ligelizumab, IgE/GI …
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Kang YK, et al. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343033 Free PMC article. Clinical Trial.
PURPOSE: Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kina …
PURPOSE: Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inh …
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T, Falkenhorst J, Schulz T, Fletcher BS, Teuber A, Krzeciesa D, Klooster I, Lundberg M, Wilson L, Lategahn J, von Mehren M, Grunewald S, Tüns AI, Wardelmann E, Sicklick JK, Brahmi M, Serrano C, Schildhaus HU, Sievers S, Treckmann J, Heinrich MC, Raut CP, Ou WB, Marino-Enriquez A, George S, Rauh D, Fletcher JA, Bauer S. Mühlenberg T, et al. J Clin Oncol. 2024 Apr 20;42(12):1439-1449. doi: 10.1200/JCO.23.01197. Epub 2024 Feb 26. J Clin Oncol. 2024. PMID: 38408285
PURPOSE: Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary KIT mutations, and clonal heterogeneity of these secondary mutations represents a major treatment obstacle. ...KIT-inhibitor combinations may suppress resistance becaus …
PURPOSE: Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary KIT mutations, and clonal heterogen …
Kit mutants and gastrointestinal physiology.
Sanders KM, Ward SM. Sanders KM, et al. J Physiol. 2007 Jan 1;578(Pt 1):33-42. doi: 10.1113/jphysiol.2006.122473. Epub 2006 Nov 9. J Physiol. 2007. PMID: 17095561 Free PMC article. Review.
It has been difficult to study these cells under native conditions, but great insights about the function of ICC have come from studies of genetic models with loss-of function mutations in the Kit signalling pathway. First it was discovered that signalling via Kit ( …
It has been difficult to study these cells under native conditions, but great insights about the function of ICC have come from studies of g …
Latest advances in adult gastrointestinal stromal tumors.
Florou V, Wilky BA, Trent JC. Florou V, et al. Future Oncol. 2017 Oct;13(24):2183-2193. doi: 10.2217/fon-2017-0245. Epub 2017 Oct 6. Future Oncol. 2017. PMID: 28984483 Review.
Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. ...New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple …
Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a pre …
Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry.
Hirota S. Hirota S. Transl Gastroenterol Hepatol. 2018 May 12;3:27. doi: 10.21037/tgh.2018.04.01. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 29971258 Free PMC article. Review.
Therefore, not only spindle cell tumors but also epithelioid cell ones developing in the GI tract are subject to the differential diagnoses of GISTs. GISTs are basically positive for KIT, a receptor tyrosine kinase (RTK) encoded by protooncogene c-kit, by imm …
Therefore, not only spindle cell tumors but also epithelioid cell ones developing in the GI tract are subject to the differential dia …
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. Joensuu H, et al. J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605837
PURPOSE: Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. ...RESULTS: We identified 301 different single mutations in KIT …
PURPOSE: Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the …
KIT genetic alterations in anorectal melanomas.
Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C, Massi D. Santi R, et al. J Clin Pathol. 2015 Feb;68(2):130-4. doi: 10.1136/jclinpath-2014-202572. Epub 2014 Nov 14. J Clin Pathol. 2015. PMID: 25398993
METHODS: Primary AR MM (n=31) and GI metastatic melanoma (n=27) were studied for KIT mutations on exons 11, 13, 17 and 18 by high-resolution melting analysis, direct sequencing and c-KIT expression by immunohistochemistry. ...Increased KIT copy number …
METHODS: Primary AR MM (n=31) and GI metastatic melanoma (n=27) were studied for KIT mutations on exons 11, 13, 17 and 18 by h …
592 results